b
cell
activ
factor
tumor
necrosi
factor
tnf
famili
baff
also
known
bli
system
extens
review
sinc
discoveri
particularli
field
autoimmun
baff
crucial
role
especi
system
lupu
erythematosu
sle
review
vincent
et
al
role
baff
blymphocyt
autoimmun
result
clinic
success
sle
patient
almost
overshadow
potenti
role
system
immunolog
field
transplantationgraft
versu
host
diseas
gvhd
chronic
variabl
immunodefici
cvid
infect
allergi
instanc
baff
emerg
critic
factor
variou
hematolog
lymphoid
cancer
inde
number
translat
studi
link
progress
variou
malign
baff
welldescrib
prosurviv
activ
suggest
use
baffneutr
therapi
may
extend
addit
indic
particular
cancer
furthermor
baff
system
recent
describ
preeclampsia
data
suggest
baff
april
signal
pathway
import
cell
viabil
human
placenta
review
detail
latest
result
view
novel
function
baff
april
system
outsid
autoimmun
arena
howev
role
baff
autoimmun
remain
one
import
baff
system
play
key
role
develop
autoimmun
especi
system
lupu
erythematosu
sle
often
lead
assumpt
baff
mostli
b
cell
factor
specif
role
autoimmun
focu
baff
autoimmun
driven
pharmaceut
success
recent
approv
novel
target
therapi
belimumab
releg
potenti
role
baff
background
far
slespecif
baff
system
much
broader
relev
infect
cancer
allergi
review
provid
latest
view
addit
role
baff
system
health
diseas
well
updat
baff
autoimmun
particular
focu
current
clinic
trial
elsevi
ltd
right
reserv
develop
decad
review
also
provid
updat
current
clinic
trial
one
import
paradigm
shift
blymphocyt
biolog
last
fifteen
year
realiz
express
b
cell
receptor
bcr
b
cell
import
enough
surviv
matur
inde
baff
emerg
critic
b
cell
surviv
factor
without
matur
b
cell
occur
prolifer
induct
ligand
april
also
known
identifi
cell
growth
stimul
variou
cancer
cell
line
baff
april
produc
type
ii
transmembran
protein
like
mani
tnf
famili
ligand
proteolyt
cleav
furin
proteas
site
releas
solubl
form
baff
may
remain
membranebound
form
although
process
solubl
baff
requir
b
cell
homeostasi
contrast
april
cleav
golgi
site
prior
releas
normal
exist
solubl
form
outsid
cell
origin
recent
report
except
aprild
malign
isoform
april
lack
furin
cleavag
site
remain
membranebound
leukemia
cell
precursor
anoth
membranebound
variat
twepril
hybrid
protein
april
tweak
tnfrelat
weak
induc
apoptosi
result
transsplic
adjac
gene
baff
activ
ligand
homotrim
main
form
baff
found
circul
howev
unlik
tnf
famili
cytokin
form
baff
obtain
physiolog
ph
condit
form
also
abl
bind
receptor
form
describ
mous
model
remain
unclear
whether
detect
human
mous
baff
also
membranebound
splice
variant
dbaff
may
form
trimer
normal
baff
protein
reduc
baff
avail
although
form
baff
modul
b
cell
popul
april
baff
interact
heparin
sulfat
proteoglycan
hspg
structur
unrel
tnf
receptor
may
act
increas
april
signal
local
site
concentr
april
cell
surfac
similar
form
baff
engag
mani
receptor
singl
site
see
fig
baff
april
share
two
receptor
transmembran
activ
cyclophilin
ligand
interactor
taci
also
known
b
cell
matur
antigen
bcma
also
known
april
bind
strongli
bcma
moder
taci
wherea
baff
bind
weakli
bcma
strongli
taci
addit
baff
bind
strongli
baff
receptor
baffr
also
known
three
main
receptor
baffr
taci
bcma
distinct
express
pattern
base
b
cell
develop
stage
relat
separ
function
tabl
baffr
express
absent
b
cell
precursor
bone
marrow
gain
immatur
b
cell
upon
acquir
function
b
cell
receptor
bcr
baffr
critic
surviv
matur
immatur
b
cell
mice
taci
express
highli
matur
innatelik
b
cell
margin
zone
mz
b
cell
b
cell
necessari
tindepend
type
ii
type
respons
neg
regul
b
cell
number
follicular
helper
tfh
cell
number
promot
class
switch
recombin
b
cell
signal
directli
myeloid
differenti
primari
respons
gene
taci
express
tempor
regul
taci
express
decreas
newborn
human
mice
human
taci
express
memori
b
cell
taci
mutat
detect
common
variabl
immunodefici
cvid
patient
make
frequent
mutat
gene
diseas
taci
interact
april
hspg
complex
bcma
express
restrict
plasmablast
fig
baff
april
signal
baff
express
membranebound
trimer
proteolyt
cleav
form
solubl
trimer
baff
also
exist
circul
baff
bind
strongli
baffr
taci
weakli
bcma
indic
thick
thin
arrow
respect
baff
trimer
activ
taci
effici
baff
multim
requir
baff
also
recent
describ
bind
receptor
astrocyt
neuron
call
receptor
ngr
april
cleav
intracellularli
except
aprild
found
circul
trimer
multim
associ
heparin
sulfat
proteoglycan
hspg
april
bind
strongli
bcma
weakli
taci
also
bind
hspg
baffr
primarili
express
b
cell
taci
innatelik
b
cell
bcma
plasmablast
plasma
cell
howev
receptor
found
cell
type
baffr
activ
cell
plasma
cell
pc
bcma
promot
longliv
pc
surviv
receptor
ngr
reticulon
receptor
recent
identifi
addit
high
affin
receptor
baff
ngr
express
neuron
inhibit
neuron
outgrowth
respons
baff
signal
interact
emerg
relev
central
nervou
system
cn
injuri
diseas
multipl
sclerosi
ms
associ
increas
local
product
baff
astrocyt
baff
april
predominantli
produc
myeloid
cell
recent
studi
describ
regul
express
baff
april
receptor
varieti
hematopoiet
nonhematopoiet
cell
lineag
tabl
sever
recent
studi
report
new
mechan
regul
baff
express
baff
product
monocyt
major
sourc
baff
product
suppress
intraven
immunoglobulin
ivig
treatment
vitro
chronicinflammatori
demyelin
polyneuropathi
cidp
patient
elev
circul
baff
level
baff
express
upregul
estrogen
consist
strong
gender
bia
observ
baffdriven
autoimmun
patient
murin
diseas
model
baff
express
increas
interferonalpha
ifna
signal
b
celldefici
baffdefici
mice
protect
ifnadriven
system
lupu
erythematosu
sle
reinforc
potenti
baffoverexpress
driver
autoimmun
diseas
also
support
correl
elev
circul
baff
level
sle
human
review
vincent
et
al
light
promin
role
baff
autoimmun
complet
surpris
elev
level
baff
also
associ
chronic
gvhd
cgvhd
patient
receiv
allogen
hematopoiet
stem
cell
transplant
hsct
therapi
mirror
aspect
immunodefici
autoimmun
inde
increas
serum
baff
level
alloantibodi
titer
strongli
suggest
role
b
cell
gvhd
pathogenesi
b
cell
repertoir
gvhd
microenviron
defin
identifi
increas
number
germin
center
gc
b
cell
postgc
plasmablastlik
cell
cgvhd
lung
patient
bronchiol
obliteran
syndrom
bo
often
fatal
patient
increas
number
lo
b
cell
suggest
role
transit
type
b
cell
diseas
elev
serum
baff
concentr
combin
lo
cell
number
success
use
assess
risk
bo
hsct
recipi
baff
singl
nucleotid
polymorph
snp
also
identifi
show
use
independ
predictor
gvhd
phenotyp
allogen
transplant
serum
baff
level
also
show
predict
use
monitor
diseas
activ
first
month
follow
extracorpor
photopheresi
ecp
treatment
refractori
cgvhd
furthermor
baff
level
also
use
delin
kidney
transplant
recipi
normal
abnorm
renal
function
reject
abnorm
renal
function
higher
level
surfac
baff
cell
popul
year
transplant
moder
igg
deposit
suggest
autoantibodi
product
b
cell
common
featur
cgvhd
delay
b
cell
reconstitut
month
allogen
transplant
b
cell
lymphopenia
also
correl
hypogammaglobulinemia
coincid
increas
hi
b
cell
contrast
autolog
hsct
drastic
increas
number
transit
b
cell
follow
transplant
possibl
suggest
competit
reconstitut
b
cell
deplet
activ
potenti
autoreact
b
cell
suggest
use
rituximab
studi
shown
stabli
induc
chang
b
cell
distribut
month
rituximab
therapi
notabl
increas
igd
b
cell
number
decreas
activ
baffr
lo
lo
b
cell
interestingli
howev
baff
level
often
seen
neg
prognost
factor
increas
rituximab
treatment
potenti
due
diminish
number
baff
receptorexpress
b
cell
feedback
loop
respons
loss
b
cell
sentiment
remain
baff
viabl
therapeut
target
glare
disconnect
increas
serum
baff
poor
reconstitut
b
cell
higher
baffr
express
activ
b
cell
includ
b
cell
suggest
mechan
work
b
cell
expans
necessari
redistribut
b
cell
baff
modul
may
simpl
therapi
inhibit
taci
andor
bcma
may
appropri
target
gc
postgc
b
cell
classic
pictur
baff
system
dynam
slowli
evolv
complex
pictur
interwoven
regulatori
function
downstream
signal
design
alter
cellular
surviv
growth
migrat
central
role
baff
autoimmun
establish
still
develop
understand
contribut
baff
system
malign
current
conceptu
pictur
posit
baff
april
primarili
pathogen
player
microenviron
solid
hematolog
tumor
elev
serum
baff
level
deriv
neutrophil
note
oral
caviti
cancer
associ
promot
invas
migrat
activ
hypox
breast
cancer
cell
line
studi
correl
increas
serum
tnf
level
angiogenesi
poor
prognosi
multipl
myeloma
overexpress
baff
shown
enhanc
cmyc
express
promot
chronic
lymphocyt
leukemia
cll
like
diseas
via
activ
canon
ikk
mycbaff
tg
mice
baff
product
stromal
support
cell
microvascular
endotheli
cell
mvec
shown
trigger
aberrantli
express
surfac
cll
b
cell
support
import
support
stroma
cancer
cell
surviv
explain
observ
ex
vivo
apoptosi
isol
cll
cell
given
observ
might
use
incorpor
measur
serum
baff
level
exist
score
system
prognost
use
baff
level
alreadi
shown
promis
cll
combin
express
mutat
statu
follicular
lymphoma
express
baff
baffr
elev
coincid
inferior
progressionfre
surviv
pf
suggest
overexpress
baff
secondari
elev
express
baffr
therefor
increas
sensit
baff
prostat
cancer
appear
except
case
epitheli
cellderiv
baff
protect
periglandular
lymphocyt
surviv
limit
tumor
expans
latter
studi
provid
rational
futur
studi
includ
assess
baff
receptor
phenotyp
diseas
context
fulli
understand
diseas
dynam
baff
may
polar
cellular
behavior
inde
investig
cellular
program
b
cell
tumor
led
identif
novel
baff
splice
variant
aptli
name
isoform
exagger
product
sle
cll
therebi
enhanc
autocrin
baff
secret
transcript
level
act
transcript
factor
first
report
cytokin
selfregul
transcript
level
may
first
piec
unexplor
layer
baff
regul
provid
support
aberr
autocrin
feedback
seen
patholog
suggest
pathogen
baff
signal
may
selfsubstanti
possibl
implic
futur
therapeut
strategi
similarli
april
isoform
b
g
e
detect
preb
acut
lymphoblast
leukemia
cell
potenti
contribut
previous
baffattribut
b
cell
surviv
find
emerg
backdrop
increas
focu
baff
receptor
surprisingli
solubl
bcma
isoform
identifi
function
yet
elucid
suggest
excit
prospect
natur
decoy
produc
regul
level
free
baff
april
overexpress
taci
detect
multipl
myeloma
thyroid
carcinoma
correl
analys
suggest
taci
express
use
prognost
marker
lymphoma
interestingli
overexpress
april
found
coincid
overexpress
hspg
known
coreceptor
april
bind
taci
renew
specul
hspg
may
act
primari
receptor
april
addit
coreceptor
function
baffr
implic
nuclear
interact
ikkb
nfkbcrel
normal
health
neoplast
b
cell
includ
nhl
b
cell
enhanc
histon
phosphoryl
bind
nfkb
promot
induc
gene
includ
bclxl
strikingli
baff
complic
alreadi
complic
pictur
baff
system
regul
receptor
transcript
regul
exert
effect
via
chromatin
remodel
addit
classic
nfkb
activ
membran
surfac
mutat
baff
receptor
also
emerg
critic
factor
diseas
mechan
emerg
prognost
power
substitut
mutat
baffr
nonhodgkin
lymphoma
nhl
patient
increas
recruit
surprisingli
demonstr
first
time
essenti
compon
downstream
baffr
signal
nhl
health
inhibit
baff
receptor
strong
focal
point
therapeut
develop
merck
phase
ib
trial
atacicept
inhibitor
baff
april
shown
agent
well
toler
moder
dosag
current
data
clinic
activ
cll
trial
avail
competit
inhibit
fusion
protein
compris
baff
toxin
gelonin
shown
promis
efficaci
promot
tumor
clearanc
childhood
combin
mobil
agent
antagonist
similar
strategi
employ
mutant
baff
fuse
protein
telomeras
revers
transcriptas
inhibitor
also
effect
select
kill
baff
receptor
express
burkitt
lymphoma
line
latter
exampl
reinforc
grow
evid
baff
function
confin
nfkb
activ
prosurviv
transcript
activ
direct
alter
immunosenesc
checkpoint
target
cell
chromatinlevel
alter
prolif
capac
ultim
surviv
develop
prefac
develop
new
gener
cancer
therapeut
mani
report
last
five
year
implic
baff
april
context
infect
review
recent
find
respect
baff
april
viral
bacteri
parasit
infect
induct
baff
result
viral
infect
report
viral
infect
diverg
hepat
c
human
immunodefici
viru
hiv
respiratori
syncyti
viru
rsv
infect
influenza
addit
cell
line
infect
vitro
virus
includ
dengu
viru
sendai
viru
epsteinbarr
viru
ebv
upregul
baff
express
exampl
april
express
assess
howev
one
studi
look
coronavirusinduc
encephalomyel
describ
upregul
april
express
ifng
independ
conflict
result
follow
rsv
infect
mani
observ
note
baff
upregul
observ
follow
viral
infect
ifndepend
monocyt
shown
releas
baff
respons
ifn
treatment
inde
sendai
viru
infect
monocyt
rsv
infect
bronchial
epitheli
cell
ssrna
virus
shown
abrog
block
ifn
signal
import
ifnsign
underlin
interprim
anr
studi
group
studi
show
patient
acut
infect
treat
treatment
combin
antiretrovir
therapi
produc
higher
antihiv
antibodi
titer
broader
specif
patient
treat
antiretrovir
therapi
alon
ifn
treatment
result
higher
level
baff
success
treatment
attribut
part
increas
baff
signal
whether
increas
baff
alon
without
increas
ifn
treatment
would
prove
efficaci
trial
test
whether
upregul
baff
viral
infect
product
inflamm
direct
effect
viral
infect
baffproduc
cell
whether
baff
necessari
key
produc
antivir
antibodi
still
remain
determin
differ
virus
infect
differ
cell
type
level
baff
secret
differ
one
celltyp
anoth
macrophag
neutrophil
dendrit
cell
capabl
produc
high
amount
baff
whilst
epitheli
cell
line
mucos
layer
shown
abl
modestli
upregul
baff
secret
result
infect
nonetheless
thought
play
import
role
local
respons
human
mous
b
cell
shown
upregul
baff
april
express
result
ebv
infect
human
ebv
b
cell
line
produc
compar
level
baff
april
human
myeloid
cell
line
test
tabl
ebvinfect
b
cell
line
express
baff
april
express
baffr
taci
bcma
transcript
thu
infect
ebv
result
engag
baffrtacibcma
autocrin
baff
april
led
class
switch
nfkb
activ
thu
whilst
baff
april
play
import
role
contain
ebv
infect
sustain
baff
april
express
lead
inappropri
lymphoprolifer
underscor
import
limit
express
baff
april
appropri
situat
timefram
hivinfect
patient
also
suffer
b
cell
dysregul
lead
lymphoma
complic
ebvrel
propos
lymphoma
result
polyclon
bcell
activ
caus
hivinfect
mdc
secret
baff
inflammatori
cytokin
vicin
b
cell
express
receptor
baff
studi
investig
role
baff
april
provid
protect
influenza
virusinfect
mice
found
block
baff
alon
effect
antivir
antibodi
titer
system
local
block
baff
april
use
tacifc
result
signific
drop
antivir
igg
system
bal
group
show
import
receptor
taci
mainten
antiinfluenza
respons
taci
mice
mount
antivir
respons
compar
wt
day
day
postinfect
antivir
titer
taci
mice
declin
significantli
inde
taci
shown
import
promot
sustain
express
b
cell
respond
protein
antigen
studi
bring
role
april
focu
suggest
underappreci
member
tnf
famili
deserv
attent
one
exampl
highlight
import
baffapril
system
defens
bacteri
infect
subset
cvid
patient
mutat
taci
baffr
often
present
recurr
bacteri
sinopulmonari
infect
although
fact
also
patient
taci
baffr
mutat
asymptomat
tell
us
genet
environment
factor
contribut
phenotyp
howev
mirror
cvid
patient
mutant
taci
baffr
mice
lack
taci
treat
taciig
mice
defici
baffr
defici
humor
immun
tcell
independ
antigen
includ
encapsul
bacteri
pathogen
streptococcu
pneumonia
baffrdefici
mice
almost
matur
b
cell
surpris
mice
reduc
antibodi
titer
howev
taci
mice
demonstr
import
taci
signal
gener
function
antibodi
respons
anim
b
cell
elev
number
diminish
capac
neonat
mount
protect
respons
bacteri
polysaccharid
virus
may
due
reduc
express
taci
bcma
baffr
b
cell
thu
decreas
abil
gener
switch
antibodi
respons
although
neonat
also
express
low
level
similar
report
viral
infect
patient
activ
pulmonari
tuberculosi
elev
level
ifn
show
elev
level
baff
april
role
baff
malari
infect
subject
scrutini
last
two
year
studi
start
assess
role
baffapril
system
parasit
infect
mous
model
malaria
infect
demonstr
malari
infect
result
decreas
proport
dc
express
baff
overexpress
baff
malarialspecif
antibodi
secret
cell
number
increas
mice
protect
lethal
malaria
infect
whilst
level
baff
secret
local
dc
investig
human
system
level
baff
increas
acut
malari
infect
ifng
howev
level
baffr
b
cell
reduc
acut
infect
human
suggest
defect
baff
signal
may
key
poor
humor
respons
despit
frequent
antigen
exposur
observ
malariaendem
area
togeth
studi
underlin
import
baff
april
develop
appropri
respons
infect
underscor
seriou
consequ
aris
dysregul
baff
product
follow
infect
studi
also
highlight
import
understand
regul
baff
follow
infect
context
risk
develop
autoimmun
increas
ifna
describ
sle
patient
suggest
infect
lead
elev
baff
trigger
pathogenesi
individu
genet
predispos
lupu
cvid
one
common
immunodefici
syndrom
characteris
reduct
antibodi
product
particular
igg
iga
igm
poor
respons
vaccin
pathogen
exposur
review
result
cvid
patient
vulner
infect
especi
respiratori
tract
immun
disord
autoimmun
manifest
affect
cvid
patient
etiolog
cvid
still
much
debat
appear
link
variou
genet
defect
affect
immun
function
although
inherit
pattern
unclear
mutat
delet
number
immun
gene
import
b
cell
function
associ
cvid
case
induc
costimul
ico
recent
larg
bodi
work
identifi
seri
mutat
taci
gene
found
cvid
patient
homozygos
variant
taci
gene
confirm
number
cvid
patient
heterozygos
variant
also
describ
cvid
patient
common
variant
affect
extracellular
domain
locat
transmembran
domain
heterozygos
common
homozygos
work
dissect
mutat
lead
impair
taci
function
first
show
mutat
form
taci
interfer
taci
signal
associ
wt
taci
absenc
ligand
henc
form
signalingdefect
oligomer
receptor
complex
later
work
look
equival
taci
mutat
mice
demonstr
b
cell
function
impair
mice
heterozyg
mutat
suggest
mutat
impair
taci
function
heterozygot
via
haploinsuffici
mice
lack
taci
develop
defect
resembl
cvid
patient
reduc
iga
level
impair
respons
tindepend
antigen
problem
appear
link
part
role
taci
maintain
express
essenti
pc
gener
persist
yet
rel
cvid
patient
often
carri
taci
mutat
without
immunolog
abnorm
interestingli
b
cell
cvid
patient
healthi
rel
defect
vitro
particular
respons
activ
taci
stimul
contrast
vitro
igg
iga
product
healthi
relativederiv
b
cell
normal
compar
b
cell
cvid
rel
therefor
mutat
taci
gene
sole
contribut
factor
may
facilit
emerg
cvid
combin
contribut
factor
baffr
essenti
b
cell
surviv
therefor
domin
mutat
baffr
gene
like
lead
immunodefici
inde
baffr
variant
present
heterozyg
state
identifi
cvid
patient
low
b
cell
number
variant
appear
polymorph
affect
baffr
express
yet
signal
variant
test
anoth
report
describ
sibl
carri
homozyg
baffr
gene
delet
prevent
baffr
protein
express
yet
one
sibl
recurr
infect
remain
rel
healthi
sibl
reduc
b
cell
number
well
reduc
igm
igg
level
iga
level
remain
within
normal
rang
taci
mutat
patient
critic
iga
product
mice
may
explain
differ
therefor
similar
individu
treat
b
cell
deplet
agent
belimumab
incid
infect
baffrnul
patient
may
vari
one
individu
anoth
depend
addit
factor
andor
exposur
pathogen
reason
defect
baffr
taci
function
certainli
increas
individu
vulner
immunodefici
addit
factor
requir
precipit
clear
cvid
clinic
manifest
recent
number
research
articl
report
role
baffapril
system
asthma
howev
role
system
airway
inflamm
still
remain
unclear
often
controversi
earli
work
look
mous
model
airway
inflamm
show
mice
overexpress
baff
baff
tg
mice
protect
airway
inflamm
compar
wt
anim
yet
two
independ
studi
look
use
taciig
decoy
receptor
neutral
baff
april
mous
model
show
protect
effect
protect
anim
airway
inflamm
mous
model
airway
inflamm
driven
thelper
effector
cell
baff
tg
produc
higher
number
regulatori
cell
treg
may
inhibit
function
cell
baff
tg
mice
altern
taciig
also
block
april
baff
april
may
play
role
model
seem
case
april
appear
block
effector
respons
april
mice
suscept
airway
inflamm
compar
wt
anim
human
asthma
earli
work
show
airway
epitheli
cell
produc
baff
moreov
segment
allergen
challeng
allerg
patient
lead
local
releas
baff
group
also
provid
evid
baff
play
role
patholog
chronic
rhinosinus
nasal
polyp
work
korean
cohort
children
show
level
baff
sputum
increas
one
studi
suggest
measur
serum
baff
level
may
serv
novel
diagnost
paramet
asthma
yet
anoth
studi
suggest
factor
stem
cell
factor
scf
reliabl
indic
interestingli
emerg
work
look
taci
mutat
swedish
children
asthma
describ
rare
mutat
taci
gene
correl
increas
risk
asthma
symptom
none
mutat
affect
iga
product
conclus
role
baff
human
asthma
remain
unclear
work
need
done
ascertain
role
baffapril
system
function
igeproduc
b
cell
mast
cell
neutrophil
airway
macrophag
dc
well
regul
effector
cell
role
baff
system
autoimmun
baff
system
autoimmun
mice
baff
tg
mice
develop
gren
syndrom
ss
like
syndrom
enlarg
b
cell
compart
lymphoid
organ
high
titer
antidoubl
strand
dna
dsdna
antibodi
rheumatoid
factor
rf
hypergammaglobulinemia
circul
immun
complex
glomerulonephr
immunoglobulin
ig
deposit
moreov
slepron
mice
newzealand
black
newzealand
white
nzbxnzw
bxsb
mrllprlpr
mice
increas
serum
baff
level
baff
blockad
led
reduc
diseas
manifest
interestingli
baff
appear
also
play
central
role
pathogenesi
autoimmun
arthriti
serum
baff
level
reportedli
elev
collageninduc
arthriti
cia
mous
model
experiment
model
rheumatoid
arthriti
ra
moreov
baff
gene
silenc
cia
mice
abrog
autoimmun
arthriti
develop
investig
role
april
cia
led
conflict
result
cia
incid
report
lower
april
mice
april
tg
mice
addit
differ
genet
modif
two
mice
strain
genet
background
also
differ
mice
autoimmun
prone
even
without
overexpress
april
april
mice
use
background
exact
role
april
experiment
ra
remain
clarifi
note
cia
well
adjuv
arthriti
rat
anoth
experiment
model
ra
experienc
improv
arthriti
develop
taciig
administr
block
baff
april
numer
human
autoimmun
diseas
share
variou
pathogen
pathway
includ
baffapril
pathway
fact
serum
baff
april
level
reportedli
increas
proport
patient
suffer
sle
primari
gren
syndrom
pss
ra
immun
thrombocytopenia
ms
system
sclerosi
myeloperoxidas
antineutrophil
cytoplasm
autoantibodyassoci
renal
vascul
baff
myasthenia
gravi
baff
grave
diseas
baff
autoimmun
pancreat
baff
antiglomerular
basement
membran
gbm
antibodi
diseas
review
vincent
et
al
patient
suffer
autoimmun
diseas
elev
serum
baff
level
potenti
delin
subset
individu
suffer
distinct
baffdriven
diseas
share
distinct
immunolog
phenotyp
tabl
tabalumab
alreadi
show
earli
clinic
effici
ra
howev
recent
random
placebocontrol
trial
rct
tabalumab
meet
primari
endpoint
week
ra
patient
inadequ
respons
tnf
inhibitor
anoth
rct
ra
patient
inadequ
respons
mtx
biolog
tabalumab
met
primari
endpoint
week
two
studi
initi
transient
increas
decreas
b
cell
well
matur
igd
b
cell
wherea
igd
memori
b
cell
increas
note
reduct
igm
iga
one
studi
igg
level
patient
receiv
tabalumab
compar
placebo
observ
recent
uncontrol
openlabel
studi
show
ra
patient
receiv
tabalumab
reduc
total
number
b
cell
specif
matur
b
cell
throughout
studi
period
without
reach
total
deplet
memori
b
cell
rapidli
increas
week
almost
remain
increas
week
median
time
b
cell
recoveri
sinc
last
subcutan
inject
week
serum
iga
igm
igg
decreas
week
b
cell
subset
ig
alter
associ
increas
rate
infect
highlight
satisfactori
safeti
profil
tabalumab
recent
openlabel
extens
studi
follow
rct
week
ra
patient
receiv
stabl
dose
methotrex
mtx
report
sustain
longterm
effici
drug
week
week
accord
american
colleg
rheumatolog
acr
european
leagu
rheumat
eular
criteria
high
rate
infect
dosedepend
manner
report
phase
ii
studi
involv
relapsingremit
ms
patient
recent
complet
clinicaltrialsgov
identifi
clinic
data
publish
far
blisibimod
also
known
peptibodi
fusion
polypeptid
protein
produc
escherichia
coli
target
solubl
membran
baff
blisibimod
compos
novel
baff
bind
domain
link
nterminu
human
fc
domain
pearlsc
rct
phase
iib
clinic
trial
sle
recent
complet
decemb
clinicaltrialsgov
identifi
howev
avail
data
come
pharmaceut
compani
websit
publish
articl
includ
inform
pertain
phase
iib
trial
current
avail
public
domain
belimumab
also
known
recombin
fulli
human
mab
target
solubl
baff
review
fairfax
et
al
belimumab
efficaci
sle
report
two
phase
iii
trial
belimumab
first
sole
food
drug
administr
fda
approv
biolog
sle
recent
data
report
adequ
safeti
profil
well
sustain
efficaci
belimumab
plu
standard
therapi
sle
patient
seven
year
excess
patientyear
particularli
presenc
autoantibodi
baselin
decreas
autoantibodi
level
steroid
spare
effect
observ
phase
ii
studi
activ
ra
patient
belimumab
plu
standard
care
show
adequ
safeti
profil
biolog
efficaci
signific
decreas
rf
b
cell
clinic
efficaci
accord
criteria
except
belimumab
mgkg
p
result
avail
clinicaltrialsgov
identifi
publish
yet
pss
belimumab
current
ongo
phase
ii
clinic
trial
clinicaltrialsgov
identifi
open
label
beliss
studi
involv
pss
patient
receiv
belimumab
author
report
particular
improv
glandular
domain
nonmalign
parotid
swell
well
decreas
diseas
activ
score
essdai
formal
eular
gren
syndrom
diseas
activ
index
week
phase
ii
trial
studi
effect
belimumab
desensit
sensit
patient
await
kidney
transplant
termin
due
lack
efficaci
primari
goal
clinicaltrialsgov
identifi
atacicept
chimer
recombin
fusion
protein
compris
extracellular
domain
taci
receptor
link
human
fc
domain
atacicept
inhibit
b
lymphocyt
stimul
neutral
baff
april
heterotrim
activ
induc
signific
deplet
pc
note
april
implic
pc
surviv
antibodi
product
mice
human
mice
monkey
atacicept
reduc
serum
igm
level
inhibit
igm
respons
tdepend
antigen
data
mice
show
taciig
inhibit
b
cell
matur
surviv
cell
activ
cell
independ
mz
b
cell
respons
mous
model
taciig
also
significantli
decreas
pc
number
spleen
bm
howev
taciig
treatment
reduc
number
mous
memori
b
cell
activ
longterm
humor
immun
surviv
independ
baff
april
biolog
chang
respons
taciig
associ
reduc
diseas
score
prolong
surviv
slepron
mice
two
phase
ib
studi
atacicept
treatment
show
safeti
profil
reduc
serum
igm
iga
igg
level
well
reduc
matur
total
b
cell
number
doserel
manner
sle
patient
note
promis
effect
diseaseact
measur
report
unfortun
rct
phase
iiiii
trial
concomit
newli
initi
corticosteroid
mycophenol
mofetil
mmf
activ
lupu
nephriti
ln
stop
due
increas
rate
infect
pronounc
declin
serum
igg
level
import
note
reduct
serum
igg
level
start
initi
mmf
corticosteroid
name
two
week
atacicept
induct
interestingli
sle
patient
signific
kidney
diseas
sever
renal
disord
exclud
two
previou
phase
ib
studi
four
sle
patient
receiv
atacicept
phase
ii
iii
studi
character
activ
ln
high
level
proteinuria
may
disrupt
igg
excret
well
drug
pharmacokinet
anoth
phase
iiiii
studi
involv
lupu
patient
without
activ
cn
sle
activ
moder
sever
glomerulonephr
complet
clinicaltrialsgov
identifi
publish
data
avail
strikingli
diseas
activ
worsen
ms
patient
receiv
atacicept
phase
ii
clinic
trial
clinicaltrialsgov
identifi
lead
termin
latter
well
two
clinic
trial
one
ms
clinicaltrialsgov
identifi
one
optic
neuriti
clinicaltrialsgov
identifi
ra
atacicept
meet
primari
efficaci
end
point
two
phase
ii
clinic
trial
despit
accept
safeti
profil
signific
biolog
activ
previous
report
phase
ib
studi
ra
patient
recent
phase
ii
rct
clinic
trial
studi
effect
atacicept
combin
rituximab
rtx
ra
patient
report
hypersensitivityrel
event
ataciceptrtx
combin
group
compar
rtx
monotherapi
differ
regard
clinic
respons
infect
rate
two
group
antibodi
toward
antibaff
therapi
pay
attent
product
antidrug
antibodi
adab
chronic
inflammatori
diseas
shown
limit
pharmacodynam
pharmacokinet
monoclon
antibodi
neutral
tnf
therebi
influenc
diseas
activ
fact
adab
format
associ
lower
serum
tnf
inhibitor
drug
level
advers
event
drug
failur
diseas
use
immunosuppress
agent
combin
tnf
inhibitor
appear
reduc
incid
antibodi
format
drug
preval
adab
invers
associ
dose
addit
use
mtx
chronic
inflammatori
diseas
ra
review
vincent
et
al
thu
adab
could
possibl
explain
part
failur
antibaff
therapi
patient
especi
receiv
immunosuppress
demonstr
studi
involv
antitnf
drug
well
rituximab
correl
presenc
adab
weak
b
cell
deplet
clinic
outcom
note
note
report
frequenc
antitabalumab
antibodi
ra
patient
rang
recent
studi
ra
patient
antitabalumab
adab
author
report
associ
drug
failur
advers
event
associ
adab
howev
small
sampl
size
prevent
definit
conclus
issu
whether
adab
toward
antibaff
drug
unknown
whether
potenti
adab
limit
drug
effici
remain
determin
baff
system
appear
play
major
role
immunolog
autoimmun
also
cancer
infect
transplant
allergi
immunodefici
approv
use
belimumab
system
lupu
erythematosu
import
first
step
develop
person
approach
target
baff
system
show
promis
use
broader
immunolog
context
like
mani
ligand
tnf
superfamili
baff
april
like
benefici
well
detriment
effect
domin
effect
determin
target
system
effect
patholog
autoimmun
work
need
better
understand
emerg
role
baff
system
addit
immunolog
set
baff
inhibitor
continu
show
degre
efficaci
mani
ongo
clinic
trial
challeng
alway
obtain
significantli
ad
benefit
approach
compar
current
use
biolog
better
understand
therapeut
full
mechan
action
may
help
achiev
goal
fabien
vincent
rheumatologist
special
autoimmun
broad
experi
encompass
b
cell
immunolog
molecular
immunolog
genet
base
diseas
complet
medic
train
univers
hospit
centr
caen
pari
franc
extens
experi
handl
clinic
data
well
elisa
qpcr
flow
cytometri
cell
cultur
genet
sequenc
analysi
involv
biomed
research
project
fabienn
mackay
laboratori
order
complet
phd
project
focus
role
b
cell
activ
factor
tumour
necrosi
factor
tnf
famili
baff
innat
immun
system
pathogenesi
system
lupu
erythematosu
anoth
aim
studi
character
role
baff
innat
immun
marker
increas
frequenc
lupu
autoimmun
diseas
observ
australian
indigen
popul
also
work
role
antidrug
antibodi
tnfspecif
neutral
agent
chronic
inflammatori
diseas
damien
saulepeaston
complet
undergradu
train
biotechnolog
major
biochemistri
molecular
microbiolog
continu
complet
post
graduat
diploma
medic
microbiolog
map
character
genet
resist
mechan
lethal
multidrug
resist
strain
pseudomona
aeruginosa
signific
nosocomi
pathogen
damien
sinc
spent
half
decad
profession
research
project
manag
current
second
year
phd
fund
feder
depart
innov
industri
scienc
research
diisr
damien
clinic
research
focuss
dissect
role
baff
leukemia
develop
novel
tool
clinician
track
diseas
progress
nhmrc
programm
grant
lab
garvan
discov
function
baffbl
key
bcell
surviv
factor
essenti
matur
b
lymphocyt
also
play
role
autoimmun
becam
one
lead
group
baff
research
march
professor
mackay
appoint
director
autoimmun
research
unit
adjunct
full
professor
faculti
medicin
univers
new
south
wale
new
south
wale
director
australian
societi
medic
research
asmr
current
group
continu
explor
new
function
baff
programm
studi
role
bcell
subset
innat
immun
immun
toler
autoimmun
cancer
professor
mackay
author
articlesreviewsbook
chapter
mani
highimpactfactor
journal
natur
j
exp
medicin
j
clin
invest
hindex
citat
averag
citat
per
articl
professor
mackay
receiv
thomson
reuter
australia
citat
innov
award
